No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Celadon Pharmaceuticals reiterated on Wednesday that it has yet to receive funds under its secured credit facility, and was still facing significant funding uncertainty, raising the prospect of administration if additional financing is not secured promptly.
The AIM-traded company said there had been no material progress since its 31 March update, and that it remained in discussions with the existing credit facility provider while also actively seeking alternative sources of finance.
However, Celadon cautioned that there was no guarantee of securing new funding or clarity on its timing.
Celadon previously disclosed it had limited working capital and was relying on creditor support to continue trading.
That support remained in place, and the company said it now believed it could continue operations into May.
However, it warned that without timely funding, the board may have to place the company into administration at short notice to protect stakeholder interests.
The company said it would provide further updates as appropriate.
At 1127 BST, shares in Celadon Pharmaceuticals were down 12.31% at 5.7p.
Reporting by Josh White for Sharecast.com.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.
